Full-Time

Senior Bioinformatician

Updated on 9/4/2026

Vivodyne

Vivodyne

11-50 employees

Human tissue models for preclinical testing

Compensation Overview

$214.4k - $245k/yr

Brisbane, CA, USA

In Person

PhD

Category
Biology & Biotech (1)
Required Skills
Python
R
Git
Machine Learning
Docker
AWS
Biostatistics
DevOps
Linux/Unix

Get referred to Vivodyne

See people who can refer or advise you

Requirements
  • A Ph.D. in Computational Biology, Bioinformatics, Genomics, Systems Biology, Biostatistics, or a related quantitative field with deep focus on transcriptomics and/or proteomics.
  • Two to five years of post-Ph.D. experience.
  • Strong hands-on proficiency in Python for bioinformatics, particularly Scanpy and the broader scverse ecosystem, with the ability to build alternative methods when existing tools are insufficient.
  • Deep experience with single-cell RNA sequencing datasets and workflows, including quality control, batch correction, clustering, differential expression, annotation, and integration across experiments.
  • Experience with proteomics or secretomics analysis, including Olink or similar high-dimensional panels, normalization, and cross-modality integration with transcriptomic profiles.
  • Comfort working in a Unix/Linux environment with standard development tools such as git, containers, and continuous integration/continuous delivery.
  • Ability to independently structure and execute complex analytical projects from ambiguous initial questions to concrete, reviewable outputs.
  • Strong biological intuition for distinguishing meaningful signal from artifact and discipline to validate before interpreting.
  • Ability to navigate ambiguity, prioritize, make trade-offs, and meet agreed timelines.
  • Ability to explain computational methods and biological implications to biologists, engineers, and non-technical stakeholders.
  • Proven ability to collaborate across disciplines.
  • Ability to manage multiple analyses in parallel and deliver work on predictable timelines.
  • History of method development or meaningful adaptation of existing methods to novel data types or experimental designs.
Responsibilities
  • Design, implement, and critically evaluate computational approaches for single-cell RNA sequencing, bulk RNA sequencing, secretomics, and proteomics data, including quality control, normalization, batch correction, dimensionality reduction, clustering, differential expression, trajectory analysis, and multi-dataset integration.
  • Develop or adapt methods for perturbation modeling, causal inference, network reconstruction, ligand-receptor inference, and multi-omics integration as needed.
  • Select and standardize analytical tooling based on rigorous benchmarking.
  • Architect end-to-end analysis workflows in Python and/or R using modern workflow orchestration such as Nextflow, Snakemake, or equivalent, designed for reproducible, version-controlled execution at the scale of tens to hundreds of thousands of samples.
  • Partner with software and data engineers to productionize pipelines, ensure robust data ingestion and storage, and contribute to biological data architecture decisions involving storage formats, schema design, and long-term data usability.
  • Write well-documented, testable code that engineers and scientists can run, review, and extend.
  • Own dataset analyses to answer biological and client-driven questions rigorously, grounding conclusions in the limits of the data.
  • Partner with experimental biologists to frame biological questions, design analyses, and recommend experiments and data-generation strategies to fill key gaps.
  • Produce publication-quality figures, internal reports, and partner-facing deliverables.
  • Help define benchmarking strategies for internal tissue model development.
  • Identify opportunities to leverage internal and public datasets to accelerate scientific progress.
  • Contribute to data standards, comparability, and integration of omics features into downstream machine-learning models and artificial-intelligence workflows.
  • Translate complex multi-omic analyses into clear insights for biologists, artificial-intelligence and machine-learning researchers, software engineers, and non-technical stakeholders.
  • Tailor the depth and framing of communication to the audience while maintaining scientific rigor.
Desired Qualifications
  • Industry experience.
  • Familiarity with R-based workflows, including Seurat, Bioconductor, and Monocle.
  • Experience with cloud environments such as Amazon Web Services and workflow managers.
  • Familiarity with large-scale biological data infrastructure such as AnnData/H5AD, TileDB-SOMA, or similar systems.
  • Experience with multi-modal data integration, including imaging, transcriptomics, and proteomics features.
  • Background in drug discovery, toxicology, or translational research where multi-omic data inform therapeutic decisions.
  • Experience with representation learning or machine learning for biological data, especially in collaboration with machine-learning specialists.
  • Familiarity with organoids, primary tissues, or organ-on-chip systems.

Vivodyne develops advanced human tissue models and related platforms for drug discovery. Its approach combines human tissue engineering, scalable robotics, and AI models to create preclinical systems that allow testing of drug efficacy before clinical trials. By offering these tissue models and associated services to pharmaceutical and biotech customers, Vivodyne helps researchers obtain preclinical certainty, speed up development, and reduce costs. The company differentiates itself by integrating tissue engineering with robotics and AI at scale to produce human-specific models instead of relying on traditional animal or non-human data. The goal is to improve predictability in early drug development, shorten timelines, and increase the likelihood of clinical success for therapeutic candidates.

Company Size

11-50

Company Stage

Series A

Total Funding

$80M

Headquarters

Philadelphia, Pennsylvania

Founded

2020

Get referred to Vivodyne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 2026: Eight major pharmaceutical companies paid for early access to Vivodyne.
  • 2026 hiring shows active expansion across robotics, bioinformatics, software, and lab operations.
  • Vivodyne's 43-person team grew 13.8% in 2026, signaling execution and demand.

What critics are saying

  • Vivodyne still lacks disclosed clinical validation; 96% airway concordance is one tissue, one benchmark.
  • If tissues fail to predict human outcomes, Vivodyne becomes an expensive research demo.
  • Animal-testing incumbents and organ-on-chip rivals can undercut pricing before revenue scales.

What makes Vivodyne unique

  • September 2026: Vivodyne runs 12 robotic HIVE labs and 3.1 million tissue tests yearly.
  • August 2026: Series 2 TissueDisk grows hundreds of functional human tissues on one chip.
  • Andrei Georgescu's platform combines robotics, multimodal AI, and patient-linked human tissues.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

2%

2 year growth

5%
MyChesCo
Aug 25th, 2026
Vivodyne scales human tissue testing as drugmakers sign on.

Vivodyne scales human tissue testing as drugmakers sign on. PHILADELPHIA, PA - Vivodyne has established a network of 12 automated laboratories capable of testing potential medicines on 3.1 million lab-grown human tissues annually, securing paid early access agreements with eight major pharmaceutical companies as it expands artificial intelligence-driven drug development. Discover more Merchant Services & Payment Systems Newspapers City & Local Guides The Philadelphia company estimates its annual testing capacity is twice the combined scale of every U.S. clinical trial, positioning its platform as a way for drugmakers to evaluate treatments in human tissue before testing them in patients. The operation combines robotic HIVE laboratories with Vivodyne's newly introduced Series 2 TissueDisk, a biological chip that simultaneously grows hundreds of functional human tissues. Vivodyne manufactures the disks on its own automated production line, allowing the company to scale tissue production and run controlled experiments across multiple diseases and organ systems. The platform is designed to help pharmaceutical companies assess drug targets, chemical formulations, dosing, safety and potential side effects earlier in development. Discover more Local News Public Finance Its laboratories operate without human intervention for weeks, growing tissues to maturity, administering drug combinations and cell therapies, modifying genes and collecting biological data over time. Vivodyne's Hivemind software plans experiments, directs laboratory operations, trains AI models on the results and identifies which experiments to conduct next. The company's approach uses reinforcement learning, allowing AI systems to propose interventions, observe how living tissues respond and refine subsequent experiments based on measured outcomes. Experimental results are collected through three-dimensional imaging, genetic sequencing and protein analysis, producing data on how treatments affect cells, blood vessels, immune components and molecular pathways. Vivodyne grows more than 20 types of human organ tissue, including liver, lung, intestinal, bone marrow, pancreatic, kidney, eye and lymph node tissue. Discover more City & Local Guides Traffic & Route Planners Public Finance Its disease models include fibrosis, solid tumors, inflammation, metabolic disorders and vascular disease. Each tissue sample begins with primary cells from human patients and develops into a structure containing approximately 200,000 to 500,000 cells, including blood vessels and immune components. Test compounds are delivered through those vascular networks, replicating the way medicines circulate through the bloodstream. In comparisons involving healthy and diseased patients, Vivodyne reported that its laboratory-grown airway tissue achieved a 96% concordance with the cellular composition of human airway tissue. The company's pharmaceutical programs include pulmonary tumors, multi-target biologics, cell therapies, immunosuppression, fibrosis, inflammatory diseases, messenger RNA, lipid nanoparticles, chemotherapy, antibody-drug conjugates, vaccines and drug-induced liver injuries. Some pharmaceutical partners have reserved large-scale experimental capacity, while others are collaborating with Vivodyne on drug-discovery programs. Discover more Demographics Geographic Reference "Prediction means knowing what happens when you try something new," stated Tony Bahinski, Vivodyne's chief biotechnology officer and a member of the Food and Drug Administration's science board. "And in pharma, almost everything we try is new." Chief Executive Officer and co-founder Andrei Georgescu argued that conventional testing methods and existing biological datasets are insufficient to train AI systems capable of predicting complex human responses. "To create AI that understands our intricate human biology, we need to continuously generate and train on huge amounts of human data, and we can't get that by risking people," Georgescu stated. Vivodyne is working to expand tissue production beyond its current capacity toward billions of samples as it develops computational models spanning multiple human organ systems. Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources - free for everyone. If you value that, click here to become a patron today. Discover more Travel Guides & Travelogues Traffic & Route Planners Geographic Reference

TechCrunch
Aug 19th, 2026
Biotech startup Vivodyne raises $80M to fix AI drug discovery's data problem

A biotech startup called Vivodyne has opened what it calls the world's largest "human data centre" outside San Francisco, aiming to address what it sees as a critical data problem in AI drug discovery. The company's HIVE system uses modular robotic labs to grow 20 types of human tissue, then autonomously doses and monitors them. This generates causal biological data that current AI models lack, which typically comes from animal testing or single-cell studies. Vivodyne, spun out from the University of Pennsylvania in 2021, has raised just under $80 million across two rounds led by Khosla Ventures. The company claims its tissues closely match real human organ behaviour, with its liver cells showing 94% predictive accuracy for toxicity compared to human trials. CEO Andrei Georgescu says the system already achieves twice the throughput of all animal trials in the US.

AI Cyber Australia
Aug 19th, 2026
Vivodyne introduces revolutionary ai-powered biotech labs to transform drug discovery.

Vivodyne introduces revolutionary ai-powered biotech labs to transform drug discovery. A biotech startup, Vivodyne, has launched an innovative approach to address the data limitations in AI drug discovery with their HIVE, modular robotic labs. These labs, capable of growing 20 types of human tissue, autonomously monitor and generate essential biological data for AI models - data traditionally derived from less accurate animal tests or single-cell studies. * Problem Addressed: Current AI models lack accurate human biological data, hindering progress in drug discovery and leading to ineffective outcomes, such as curing diseases in animals but not humans. * Vivodyne's Solution: CEO Andrei Georgescu explains that HIVE aims to fill these data gaps by generating human-relevant causal data, crucial for training AI models capable of intricate, real-world biological predictions. * Industry Impact: This development is set against a backdrop of ongoing debates on AI's role in curing diseases, with industry leaders like Sam Altman and Demis Hassabis making broad claims yet noting limited tangible outcomes so far. * Vivodyne's Milestones: Spun out from the University of Pennsylvania, Vivodyne recently established the largest 'human data center', raising nearly $80 million to expand their operations. Their innovative labs achieve twice the throughput compared to U.S. animal trials. * Greater Vision: The startup hopes to change the paradigm of drug creation from experimental to causality-driven, aiding in the development of combination therapies for complex diseases, enhancing the reliability of drug approval predictions, much like automotive crash tests predict safety standards. * Current and Future Steps: Although it hasn't disclosed its partners, Vivodyne is collaborating with major pharmaceutical companies to revolutionize the path to drug development, potentially transforming the healthcare landscape with AI and advanced biotechnological integration.

Yahoo
Aug 18th, 2026
Robotic 'hives' grow human tissue for 3 million drug tests a year, cutting need for lab mice.

Robotic 'hives' grow human tissue for 3 million drug tests a year, cutting need for lab mice. Wyatt Fischer Tue, August 18, 2026 at 9:24 AM PDT A Bay Area startup is taking a shot at ending animal testing, one of medicine's most persistent humanitarian and logistical problems. Drugs that appear promising in mice can fall apart once they reach humans, not to mention the suffering the animals endure. Its solution is a fleet of robotic "hives" that grow human tissue and run millions of experiments designed to catch failures long before people enter costly clinical trials. Here's what to know. According to Fast Company, Vivodyne operates south of San Francisco and is building an automated system intended to replace animal testing. Instead of making mice the primary proving ground for new medicines, the company uses mini-labs filled with living human tissue and relies on AI-designed experiments. As Fast Company noted, nearly 90% of clinical trials still fail even after a drug has passed animal testing. That gap suggests animal models often do a poor job of forecasting how human bodies will respond. The company says it has expanded to 12 robotic labs, which it calls "hives." The setup can support controlled studies on more than 3 million human tissues a year, about twice the combined capacity of all U.S. clinical trials. Work in the system begins with human cells, which can be obtained through a simple blood draw. From there, the cells are grown on "biological chips," where they form tissue structures complete with blood vessels and immune cells that resemble parts of organs, including the liver and kidney. More background. Animal studies have long been a routine checkpoint in drug development, despite their uneven record as a guide to how treatments will perform in people. A system built around human tissue could help drugmakers answer critical questions much earlier. Human tissue testing may help better determine if a treatment seems safe, if it affects the target tissue the way researchers expect, and whether there are warning signs that would otherwise surface only after enormous sums have already been spent. When trials fail late in development, the costs can be staggering, and those setbacks can delay the arrival of better medicines for patients who need them. There is also an ethical dimension. If human-tissue platforms become more accurate and scalable, they could reduce the need for animals in laboratories while improving the odds that therapies moving forward are actually relevant to human biology. What's being done? What sets Vivodyne apart is the effort to do this at industrial volume. Rather than making only a small number of organ-like samples for limited studies, the company is using robotics to produce tissues at scale and run thousands of tightly controlled tests in parallel. Within that automated workflow, the platform can administer drugs, disable genes, and measure tissue reactions. The result is a broader pool of data than traditional methods typically allow, making it easier to compare outcomes and flag ambiguity before a treatment reaches the clinic. "You have these clinical trials where there's hundreds of millions of dollars at stake... and then it fails because of some ambiguity that you could not have checked," Vivodyne CEO Andrei Georgescu said. Get TCD's free newsletters for easy tips, smart advice, and a chance to earn $5,000 toward home upgrades. To see more stories like this one, change your Google preferences here.

Yahoo Finance
Aug 15th, 2026
Khosla: AI creates 'hyperabundance' of new drugs, but testing still '18th-century

Venture capitalist Vinod Khosla says AI is generating a "hyperabundance of potential new drugs", but testing methods remain outdated. In a post on X, Khosla criticised the continued reliance on animal testing, calling it "18th-century style". He highlighted Vivodyne, a biotechnology company testing drugs using living human tissues at industrial scale. Khosla said he is working with Vivodyne on its "Virtual Human" data centre to predict patient treatment responses. The comments follow recent AI developments in drug discovery. Anthropic launched Claude Science for scientific research, whilst Takeda reported positive trial results for its AI-developed psoriasis drug. Nvidia and Eli Lilly announced a $1 billion AI co-innovation lab for drug development.